Impact of clinical pharmacist interventions on inappropriate prophylactic acid suppressant use in hepatobiliary surgical patients undergoing elective operations

Hongli Luo *, Qingze Fan, Shunlin Xiao, Kun Chen
Department of Pharmacy, the Affiliated Hospital of Southwest Medical University, Luzhou, China

* lyfyylhl@163.com

Abstract

Objective

To evaluate the impact and cost-benefit of clinical pharmacist interventions on inappropriate use of prophylactic acid suppressant in hepatobiliary surgical patients in a Chinese tertiary hospital.

Methods

A retro-prospective intervention study of patients undergoing elective operations was performed in the Department of Hepatobiliary Surgery of the Affiliated Hospital of Southwest Medical University. Patients admitted from October to December 2015 and from October to December 2016, served as the pre-intervention and the post-intervention group, respectively. Clinical pharmacist interventions in the post-intervention group included real-time monitoring medical records and recommending that surgeons prescribe prophylactic acid suppressants according to the criteria established by the hospital administration. Then, the clinical outcomes of post-intervention group were compared with the pre-intervention group which lacked pharmacist interventions. In addition, cost-benefit analysis was conducted to determine the economic effects of implementing the clinical pharmacist interventions in acid suppressant prophylaxis in perioperative period.

Results

Clinical pharmacist interventions significantly decreased the rate of the use of no indications for prophylactic acid suppressant and of the cases of inappropriate drug selection, dose, route, replacement and prolonged duration of prophylaxis ($P < 0.05$ or $P < 0.001$), resulting in significant increase by 10.65% in the percentage of cases adhering to all the criteria ($P < 0.001$). Moreover, significant reductions were found in the average usage quantity ($P < 0.001$), mean cost ($P = 0.03$) and mean duration ($P < 0.001$) of prophylaxis acid suppressant. The ratio of the mean cost savings for acid suppressants to the mean cost of pharmacist time was 13.61:1.
Conclusion

The clinical pharmacist’s real-time interventions facilitated the rational use of prophylactic acid suppressant and resulted in favorable economic outcomes in hepatobiliary surgery.

Introduction

Stress ulcer or stress related mucosal disease that appears after major stressful events such as surgery, trauma and mental illness is superficial lesions commonly involving the mucosal layer of the stomach. Previous studies showed that a serious complication, stress ulcer bleeding is rare, but the risk is higher in intensive care unit (ICU) patients than non-ICU patients [1, 2]. Without stress ulcer prophylaxis (SUP), approximately 6% of critically ill patients experience clinically significant gastrointestinal bleeding (GIB) [3]. Another study showed no decrease in bleeding rate when using SUP for non-ICU patients [4]. Thus it has been validated that the SUP was beneficial for ICU patients, but this was not the case for non-ICU patients such as general surgery patients. However, overutilization of SUP in both ICU and non-ICU patients has become increasingly common recently [5, 6]. Overutilization is defined as prescribing SUP without a documented indication or inappropriate continuation upon discharge from the hospital. To assist clinicians with appropriate use of SUP, several organizations have developed clinical practice guidelines (CPGs) for SUP [7]. For example, SUP guidelines published in 1999 by the American Society of Health-System Pharmacists (ASHP) recommended that acid suppressants should only be used for patients with at least one present risk factor, such as coagulopathies, mechanical ventilation, history of gastrointestinal ulceration or bleeding, etc [8]. Furthermore, based on the national and local circumstance, the National Health and Family Planning Commission (NHFPC) of China and Health and Family Planning Commission of Sichuan Province have incorporated the guidelines into the national drug policy and local enforcement regulation.

Despite the availability of these CPGs and internal policies, the prophylactic use of acid suppressant is still far from optimization. A retrospective analysis found that 73% of patients were prescribed SUP without an appropriate indication, with 69% of patients continuing upon discharge [9]. A prospective study showed that 91.5% of patients in the infectious disease ward who received acid suppression therapy did not have an indication for SUP [10]. A considerable portion of surgeons did not adhere to the basic principles suggested by issued guidelines for SUP [11, 12]. Analogously, the inappropriate PPIs use in the perioperative period of surgical procedures was ubiquitous in the department of hepatobiliary surgery of the affiliated hospital of Southwest Medical University, located in Luzhou, China. Our previous study indicated that the rate of PPI prescribing was up to 84.04%, yet no indication usage was 77.77% in hepatobiliary surgery of our hospital [13].

Recommended agents for SUP were proton pump inhibitor (PPI) and histamine-2 receptor antagonist (H₂RA). Overutilization of both H₂RA and PPI poses significant health risks and increases healthcare costs. The uncontrolled and probably unnecessary utilization of PPI could lead to increased risk of avoidable adverse events (such as hospital/community—acquired pneumonia and Clostridium difficile-associated diarrhoea) and potential complications (acute interstitial nephritis, fracture risk, vitamin and mineral deficiency, hypomagnesemia, etc.) and drug interactions [14–17]. The clinic adverse events of H₂RAs were mainly observed on the skin and the nervous system [18]. Therefore, to prevent these complications and avoid medical
waste, it is greatly essential to implement interventions to improve the rational use of acid suppressant prophylactic.

Special pharmacists have become an established feature of the medical stewardship landscape in hospitals, particularly antibiotic specialist pharmacists [19, 20]. A multicentre, cluster randomized, controlled trial showed that special pharmacists could play important role in reducing the frequency of a series of clinically important prescription and medication monitoring errors [21]. Recently, studies showed that pharmacist intervention decreased PPIs use in non-ICU hospitalized patients and overutilization of SUP in medical and surgical ICU [22, 23]. A retrospective study discovered that the relative reduction in the rate of inappropriate SUP in general ward patients was 83.5% after implementing pharmacist SUP managed program [24]. However, in most Chinese hospitals, clinical pharmacists are not involved in controlling irrational use of prophylactic acid suppressant, so few data are available on the effectiveness of pharmacist interventions, especially studies about the cost-benefit results of introducing clinical pharmacist as a member of SUP team. So far, we have not found any published literatures focusing on the effects of clinical pharmacist interventions on the SUP prescribing in hepatobiliary surgery. In our retro-prospective study, to decrease the inappropriate use of prophylactic acid suppressant and to reduce acid suppressant costs, a clinical pharmacist was delegated to monitor the real-time use of prophylactic acid suppressant through an internal guideline for SUP in perioperative period. The purpose of this study was to evaluate the clinical and economic impacts of clinical pharmacist interventions for SUP at a Chinese tertiary teaching hospital.

**Methods**

**Study design**

A single-center retro-prospective study was performed on patients who underwent elective operations in the Department of Hepatobiliary Surgery of the Affiliated Hospital of Southwest Medical University, which is a 3000-bed major academic tertiary hospital with an average daily admission rate of about 3500 patients per day and > 120,000 inpatient admissions annually in Luzhou, China. This study included pre-intervention and post-intervention stages. Patients admitted during the 3-month period October–December 2015 and October–December 2016 undergoing elective operations in department of hepatobiliary surgery were assigned to the pre-intervention and the post-intervention group, respectively. The pre-intervention stage was an observational period for retrospective study, in which clinical pharmacist collected medical records of the patients and discovered problems associated with acid suppressant prophylaxis in perioperative period. In the post-intervention stage, a full-time, experienced clinical pharmacist worked in the ward. The rationality of SUP in these patients was evaluated before and after the implementation of clinical pharmacist intervention program. This program was approved by the Hospital Pharmacy Administration and Therapeutics Committee (HPATC), which granted clinical pharmacist to make suggestions to the doctors, but not to modify doctor’s advice when inappropriate prescriptions occurred.

All adult (≥18 years) patients undergoing elective operations in the hepatobiliary ward were enrolled. Patients were included if they had undergone hepatobiliary surgery and had no systemic diseases. Patients were excluded if they had undergone emergency operation or any invasive operation within one month prior to hepatobiliary surgery. Also, patients were excluded if acid suppressant was prescribed for treatment of gastrointestinal diseases (eg, gastrointestinal reflux disease, peptic ulcer disease, Zollinger-Ellison or gastrointestinal hemorrhage) or taking acid suppressant within two weeks prior to surgery regardless of whether an indication was documented in the medical chart. Patients transferring from other medical...
departments or transferring to other medical departments for further treatment were excluded from analysis. In the pre-intervention stage, all medical records from October to December 2015 were exported and we randomly took samples of 250. Randomization was computer-generated. In the post-intervention stage, according to established inclusion criteria, we recruited this number (250) then stop. All eligible patients in the post-intervention stage received the clinical pharmacist intervention from October to December, 2016.

With reference to ASHP protocol, China Consensus guidelines and official document for SUP, an internal guideline for SUP in perioperative period was prepared by clinical pharmacists. After HPATC approval, the clinical pharmacist checked the prescription of every patient and advised the surgeons in charge on prescribing acid suppressant for SUP in situations when there was an indication or advised the discontinuation of acid suppressant when not warranted by patient risk factors. The indicators for rational use of prophylactic acid suppressant were judged based on the criteria as shown in Table 1.

### Pharmacist interventions

The pharmacist intervention was implemented by our previous method with some modifications [25]. During the intervention period, there was an appropriative clinical pharmacist in the hepatobiliary surgery ward. On average, the clinical pharmacist spent 4 hours on the interventions every work day. The interventions were endorsed by HPATC and the leadership of hepatobiliary surgery department, and implemented from October to December 2016. The job responsibilities of the clinical pharmacist included correcting the surgeons’ misunderstanding, monitoring medical records in real time and controlling the prescriptions of prophylactic acid suppressant on the basis of the criteria established by the hospital administration. The clinical

| Parameter                          | Justification for rational use |
|------------------------------------|--------------------------------|
| Indications                        | One of the following risk factors: |
|                                    | Severe traumatic brain or spinal cord injury (Glasgow Coma score of ≤ 10) |
|                                    | Thermal injury to > 35% of body surface area |
|                                    | Severe multiple trauma (injury severity score of > 16) |
|                                    | Difficult or complex surgery (operative time > 3 hours) |
|                                    | Severe psychological stress |
|                                    | Hepatic or renal failure |
|                                    | Mechanical ventilation for > 48 hours |
|                                    | Coagulopathy (platelet count of < 50 000 mm³ or INR > 1.5 or APTT > 2 times normal value) |
|                                    | History of gastrointestinal ulceration or bleeding within 1 year of admission |
|                                    | Dual antiplatelet therapy |
|                                    | Two or more of the following risk factors: ICU stay of greater than 1 week, occult bleeding lasting at least 6 days, high-dose use of corticosteroids (> 250 mg/d of hydrocortisone or equivalent daily), or use of non-steroidal anti-inflammatory drugs (NSAIDs) |
| Agents                             | H₂RA (low-risk for GIB), PPI (high-risk for GIB) |
| Dosage                             | Dose must be based on risk factors and concentration used for surgical prophylaxis purposes for each acid suppressant |
| Route                              | Route must be based on risk factors and surgical patients’ condition |
| Duration of prophylaxis            | Until no high risk factors, or able to tolerate enteral feeding, or not receiving mechanical ventilation or not in ICU |

https://doi.org/10.1371/journal.pone.0186302.t001
pharmacist interventions consisted of: (1) Providing educational sessions and handouts about SUP for medical teams, especially the surgical residents who prescribed acid suppressant and the nurses who executed prescriptions, including knowledge about acid suppressants’ indications, pharmacokinetics, pharmacodynamics, strength and duration. The appropriate administration route and dose were executed by nurses; (2) Before the elective operation and after the surgeons prescribed the medication, clinical pharmacist collected the information about surgical patient from electronic medical records (EMR) and surgery from hospital information system (HIS), and judged the appropriateness of the use of prophylactic acid suppressant on following aspects: indication, acid suppressant selection, dose, duration of prophylaxis, combination and replacement depending on our criteria. When obviously irrational use of prophylactic acid suppressant was identified, the clinical pharmacist communicated immediately with surgeons and provided recommendations to correct the medication errors. (3) The inappropriate orders of SUP were collected and categorized by the clinical pharmacist every day and the identified problems were reported to the hospital administration every week. The workflow of clinical pharmacist was illustrated in Fig 1.

Data collection and analysis

The data were collected from medical records of patients, containing patients’ demographics (sex, age, body mass, medical history, diagnosis and allergies), surgical procedures (name, date and duration of operation), acid suppressant usage (generic name, dose, route, frequency, duration, combinations and replacement) and cost (costs of total hospitalization, total drugs and acid suppressant). The data collection was conducted by another clinical pharmacist who was blinded to the patients’ allocation status. All costs were recorded in Chinese yuan and then converted to US dollars (exchange rate, 6.96 yuan = US $1). The final values were reported in US dollars.

Cost-benefit analysis was performed to determine the economic effects of implementing clinical pharmacist interventions for perioperative acid suppressant prophylaxis. The analysis was an evaluative technique of comparing the costs of resources consumed in implementing clinical pharmacist interventions against the benefits resulted from the interventions. The benefit-to-cost ratio was calculated by dividing the acid suppressant cost saving by the cost of time spent by clinical pharmacist. The mean acid suppressant cost saving and the mean cost of pharmacist time were applied because the numbers of patients in two groups were not equal [19]. The mean acid suppressant cost saving was gained by calculating the difference in mean cost of acid suppressant between the pre- and post-intervention phases. The mean cost of pharmacist time was calculated according to the hourly salary of clinical pharmacist and the amount of time spent by clinical pharmacist in implementing the interventions.

Data were entered and subsequently analyzed using SPSS version 22.0. For comparison between the two stages, data were analyzed using chi-squared test for categorical variables, and using student’s t-test for continuous variables to assess the significant statistical differences. A p-value of less than 0.05 was considered statistically significant.

Ethics statements

This retro-prospective study was approved by the Ethics Committee of the Affiliated Hospital of Southwest Medical University. All patients provided written informed consent to permit their information to be stored in the hospital database and used for this study.
Results

General characteristics of the patients

In the beginning, a total of 500 patients were enrolled in this study, 250 patients in each group. Then, 52 patients who didn’t meet our criteria were excluded as shown in Fig 2. At last, 448 patients in total were included for further research with 218 in the pre-intervention group and 230 in the post-intervention group as shown in Fig 2. General characteristics of the
patients in two groups were shown in Table 2. The 2 groups were similar with respect to demographics and clinical characteristics, such as sex, age, body mass, medical history, surgery type and operative duration \((P > 0.05)\). There was no significant difference in post-operative bleeding between the two groups \((P > 0.05)\) (Table 2). Three cases received therapeutic acid suppressant after surgery, so they were excluded when analyzing the rationality of prescriptions and the cost-benefit results.

**Indications and rate of prophylactic usage**

According to the established criteria for SUP in perioperative period, 38 cases and 48 cases showed indications for SUP in the pre- and post-intervention groups, respectively. However, 216 cases (100%) and 169 cases (73.80%) received SUP in pre- and post-intervention groups, respectively. In the post-intervention group, 46 cases with indications for SUP were included among the 169 cases that actually received SUP. There was a significant decrease in the rate of acid suppressant prophylaxis in the post-intervention group (Table 3).

**Frequency of prophylactic acid suppressant usage**

There were combinations or replacements of acid suppressant in some cases, which caused the same patient to be administered greater than or equal to 2 types of acid suppressant and the frequency of acid suppressant utilization to be higher than the number of patients. The frequency of prophylactic acid suppressant usage was 285 in the pre-intervention group and 186 in the post-intervention group. Significant reduction in mean number of acid suppressant used was observed after the intervention \((P < 0.001)\). As shown in Table 4, the prescription
rates of H$_2$RAs and PPIs were 0% and 13.44%, 100% and 86.56% in pre- and post-intervention group, respectively. A high rate of omeprazole prescription was observed in two stages. In the pre-intervention group, omeprazole and lansoprazole accounted for 95.44% of the acid suppressants used, followed by esomeprazole (4.56%). In the post-intervention group, omeprazole and lansoprazole accounted for 78.49% of the acid suppressants used, followed by famotidine (13.44%), pantoprazole (5.91%), esomeprazole (2.16%) (Table 4).

Table 2. General characteristics of patients in pre- and post-intervention groups.

| Characteristics                              | Pre-intervention (n = 218) | Post-intervention (n = 230) | p-value |
|----------------------------------------------|---------------------------|-----------------------------|---------|
| Male, n (%)                                  | 78 (35.78)                | 78 (33.91)                  | NS*     |
| Age, mean ± SD                               | 57.70±13.60               | 53.16±14.07                 | NS      |
| Old (>65 years), n (%)                       | 69(31.65)                 | 55(23.91)                   | NS      |
| Body mass (kg)                               | 62.15±10.04               | 65.37±12.81                 | NS      |
| Type of surgery, n (%)                       |                           |                             |         |
| Laparoscopic cholecystectomy (LC)            | 112 (51.38)               | 105 (45.65)                 | NS      |
| Open cholecystectomy (OC)                    | 46 (21.10)                | 37 (16.09)                  | NS      |
| Bile duct exploration                        | 5 (2.29)                  | 13 (5.65)                   | NS      |
| Hepatectomy                                  | 21 (9.63)                 | 27 (11.74)                  | NS      |
| Liver cyst fenestration                      | 9 (4.13)                  | 18 (7.83)                   | NS      |
| Resection of the hepatic hemangioma          | 9 (4.13)                  | 14 (6.09)                   | NS      |
| Splenectomy                                  | 9 (4.13)                  | 5 (2.17)                    | NS      |
| Pancreticoduodenectomy                       | 3 (1.38)                  | 9 (3.91)                    | NS      |
| Operative time, n (%)                        |                           |                             |         |
| >4 hours                                     | 25 (11.47)                | 32(13.91)                   | NS      |
| Post operative GI bleeding, n (%)            | 2 (0.92)                  | 1 (0.43)                    | NS      |

*NS = not significant (P > 0.05)

https://doi.org/10.1371/journal.pone.0186302.t002

Rate of inappropriate prophylactic acid suppressant use

According to the established criteria, inappropriate prophylactic acid suppressant uses in the pre- and post-intervention groups were summarized in Table 5. After intervention, obvious improvements were observed in the use of no indications for prophylactic acid suppressant and in the cases of inappropriate drug selection, dose, route, replacement and prolonged duration of prophylaxis (P < 0.05), but the proportion was not satisfied in both groups. When coadministration of omeprazole or esomeprazole with clopidogrel, generation of clopidogrel active metabolite and inhibition of platelet function were reduced, so omeprazole or esomeprazole should try to avoid using when combining with clopidogrel [26]. Five cases in pre-
intervention group were inappropriately prescribed the combination of omeprazole plus clopidogrel, but this combination was not found in post-intervention group.

Rate of correct acid suppressant administration

As shown in Table 6, a total of 17.59% of cases in the pre-intervention group and 27.22% of cases in the post-intervention group complied with the established internal criteria for the indication. None of 216 cases adhered completely to all the five criteria (indication, choice, dose, route and duration) in pre-intervention group. However, pharmacist interventions led to a remarkable increase by 10.65% in the percentage of cases adhering to all the criteria ($P < 0.001$). But the percentage of compliance to all the five criteria in post-intervention group was not satisfied, which was due to a high rate of incorrect administration route and prolonged duration of acid suppressant prophylaxis (Table 6).

Cost-benefit analysis of clinical pharmacist intervention

There was no change in the price of acid suppressants, other drugs and hospital service during the study period. There were no significant differences between the two groups regarding mean total hospitalization cost, mean total drug cost and mean hospitalization days ($P > 0.05$).

### Table 4. Prophylactic acid suppressant use in pre- and post-intervention groups.

|                          | Pre-intervention (n = 216) | Post-intervention (n = 229) | $p$-value |
|--------------------------|----------------------------|-----------------------------|-----------|
| Frequencies of prophylactic acid suppressant usage | 285 | 186 | - |
| Histamine 2 receptor antagonists, n (%) | 0 | 25 (13.44) | $<0.001$ |
| Famotidine | 0 | 25 (13.44) | - |
| Proton pump inhibitors (PPIs), n (%) | 285 (100) | 161 (68.65) | $<0.001$ |
| Omeprazole | 151 (52.98) | 105 (56.45) | - |
| Lansoprazole | 121 (42.46) | 41 (22.04) | - |
| Pantoprazole | 0 | 11 (5.91) | - |
| Esomeprazole | 13 (4.56) | 4 (2.16) | - |
| Mean number of acid suppressant used | 1.32 | 1.10 | $<0.001$ |

https://doi.org/10.1371/journal.pone.0186302.t004

### Table 5. Rate of inappropriate prophylactic acid suppressant use in surgical patients for SUP.

|                          | Pre-intervention (n = 216) | Post-intervention (n = 229) | $p$-value |
|--------------------------|----------------------------|-----------------------------|-----------|
| No indication | 178 (82.41%) | 123 (72.78%) | 0.023 |
| Inappropriate choice of acid suppressant | 5 (2.32) | 0 (0.00) | 0.046 |
| Inappropriate dose | 31 (14.35) | 12 (7.10) | 0.025 |
| Inappropriate administration route | 132 (61.11) | 63 (37.27) | $<0.001$ |
| Repeated medication | 3 (1.39) | 0 (0.00) | NS* |
| Unnecessary replacement of drugs | 56 (25.93) | 17 (10.06) | $<0.001$ |
| Unnecessary prolonged duration of prophylaxis | 141 (65.28) | 64 (37.87) | $<0.001$ |

*NS = not significant ($P > 0.05$). No indication refers to cases administrated PPIs without risk factors as shown in Table 1. Inappropriate administration choice of acid suppressant refers to the coadministration of omeprazole or esomeprazole with clopidogrel. The inappropriate administration route involves unnecessary intravenous administration when oral formulations would be more appropriate and confusing misuse of intravenous drip and intravenous injection. Repeated medication refers to cases in which patients take more than 2 PPI prescriptions at the same time. Unnecessary replacement of drugs refers to the conditions where the acid suppressant selection was discordant between the first dose and postoperative maintenance.

https://doi.org/10.1371/journal.pone.0186302.t005
Significant reductions in mean acid suppressant cost ($P < 0.05$) and mean duration of prophylaxis acid suppressant ($P < 0.001$) were observed in post-intervention groups (Table 7). The mean acid suppressant cost savings were $83.32 in the intervention stage. The total work time of the clinical pharmacist was 264 hours during 3-month intervention period. With the hourly salary of $5.31, the total cost of the pharmacists’ time was approximately $1401.84 during intervention period. The mean cost of the pharmacists’ time was calculated as the ratio of the total cost of the pharmacist’s time to the total number of cases, accordingly, yielding a mean value of $6.12. Therefore, the intervention resulted in a considerable benefit-to-cost ratio of 13.61:1 (Table 8).

### Table 6. Rate of correct* acid suppressant administration in surgical patients for SUP.

| Acid suppressant administration | Pre-intervention n (%) | Post-intervention n (%) | $p$-value |
|---------------------------------|------------------------|-------------------------|----------|
| Correct indication              | 38 (17.59)             | 46 (27.22)              | 0.023    |
| Correct indication+ correct choice | 35 (16.20)             | 46 (27.22)              | 0.008    |
| Correct indication+ correct choice+ correct dose | 26 (12.04)             | 44 (26.04)              | <0.001   |
| Correct indication+ correct choice+ correct dose+ correct route | 15 (6.94)              | 31 (18.34)              | <0.001   |
| Correct indication+ correct choice+ correct dose+ correct route+ correct duration | 0 (0.00)               | 18 (10.65)              | <0.001   |

correct* = ‘correct’ was defined as the indication, choice, dose, route or duration which met the criteria of internal guideline for SUP (Table 1).

https://doi.org/10.1371/journal.pone.0186302.t006

### Table 7. The medical cost in pre- and post-intervention groups.

|                        | Pre-intervention (n = 216) | Post-intervention (n = 229) | $p$-value |
|------------------------|-----------------------------|-----------------------------|----------|
| Mean total hospitalization cost (USD) | 4359.71 | 4106.52 | NS² |
| Mean total drug cost (USD) | 1111.57 | 1055.44 | NS |
| Mean acid suppressant cost (USD) | 161.59 | 78.27 | 0.030 |
| Mean duration of prophylaxis acid suppressant (day) | 9.48 | 4.68 | <0.001 |
| Mean hospitalization days | 13.45 | 12.50 | NS |

²NS = not significant ($P > 0.05$)

https://doi.org/10.1371/journal.pone.0186302.t007

### Table 8. Cost-benefit analysis of clinical pharmacist intervention.

| Cost of clinical pharmacist time                                      |                                        |
|---------------------------------------------------------------------|----------------------------------------|
| Hourly salary                                                       | $5.31                                  |
| 4 hours per working day × 66 working days during intervention period | 264 hours                              |
| Total cost of pharmacist time (264 hours × $5.31 per hour)          | $1,401.84                              |
| Mean cost of pharmacist time (total cost of pharmacist time ÷ 229 cases) | $6.12                                  |
| Mean acid suppressant cost reduction for 229 cases in the post-intervention group | $83.32                                  |
| Mean acid suppressant cost for 216 cases in pre-intervention group—Mean acid suppressant cost for 229 cases in the post-intervention group | $77.20                                  |

Net cost benefit

Mean acid suppressant cost reduction—Mean cost of pharmacist time $77.20

Benefit-to-cost ratio

Mean acid suppressant cost reduction: mean cost of pharmacist time 13.61:1

https://doi.org/10.1371/journal.pone.0186302.t008
Discussion

Despite growing concerns about the utilization of SUP in surgical patients, we believe that this is the first published report demonstrating improved rational use of acid suppressant prophylaxis and increased cost savings after implementation of clinical pharmacist intervention in hepatobiliary surgery.

In the present study, no indication use of acid suppressant was reduced after intervention, which demonstrated the important role of pharmacists in making prescriptions of SUP accord with the indications. However, only 27.22% of patients had an indication for SUP but 73.80% received acid suppressants in the post-intervention stage, which was similar to other recently published studies [27, 28]. At the same time, no indication use for SUP was common in many hospitals in Lebanese, USA, Switzerland, Iran [10, 12, 29, 30]. Recently published studies found that the frequency of clinically important bleeding reported was low and there was little significant reduction in bleeding with medication prophylaxis. Moreover, the side effects of PPI and H$_2$RA are not insignificant, and it is not cost-effective to use acid-suppressive therapy to prevent GIB except in the high-risk patients [23, 31]. It was confirmed that acid suppressants for SUP did not significantly reduce GIB in our study. Therefore, the pharmacist intervention could not only reduce the waste of medical resources on account of the fact that most of the prescriptions were useless, but also avoid the side effect resulting from the unnecessary use of SUP.

We proposed that there are two major factors that cause the overuse of acid suppressant in the hospital in China. On the one hand, there remained some misunderstandings about SUP in the surgeons. Before the intervention program was implemented, we conducted a survey of the surgeons about the characteristics and side effects of acid suppressant and found some misconceptions such as “acid suppressants for SUP resulted in a lower rate of post-surgical GIB” and “when PPIs and H$_2$RAs were applied for a short term, no side effects would be observed”. On the other hand, the tense doctor-patient relationship remained unchanged for decades in China. To protect themselves from lawsuits, surgeons had to prescribe additional acid suppressant to minimize the possibility of GIB. In view of this fact, the number of clinical pharmacists and working hours should be increased, which would contribute to more extensive medication education and in-depth communication with surgeons and patients.

Recommendations on agents for SUP were not consistent across developed high quality CPGs. The most of CPGs recommended using both PPI and H$_2$RA. The previous studies reported that PPI was the most frequently used acid suppressant for SUP [32, 33]. While, another study found that providing SUP with H$_2$RA therapy may reduce costs, increase survival, and avoid complications compared with PPI therapy [34]. Our guideline also recommended H$_2$RA as the preferred agent over PPI for low-risk patients for GIB in perioperative period, especially when combining with clopidogrel [35]. In our results, pharmacist intervention could avoid the inappropriate choice of omeprazole and esomeprazole and increase the usage of safer and cheaper H$_2$RA (Table 4). Nevertheless, the usage rate of H$_2$RA only accounted for 13.44% in post-intervention period because of surgeons’ misconceptions, such as “new or expensive drugs are stronger”. So, more efforts should be done in the future.

The inappropriate route and duration was more serious in our study (Table 5). The improper administration route or prolonged acid suppressant prophylaxis is, at best, of no benefit and, at worst, unnecessary drug cost and potentially harmful to patients because of the toxicity and the risk of complications. Possible reason for the high ratio of inappropriate route in our study may be that our hospital has two different brands of omeprazole for different injection method, which is easy for confusion. The one produced by AstraZeneca Pharmaceutical should be used by intravenous injection, while, the other produced by Jiangsu Aosaikang
Pharmaceutical company should be used via intravenous drip. In order to solve this problem, some methods could be adopted in the future such as pasting another eye-catching label when these drugs are distributed or changing the medicines to another brands to unify the administration route. On the other hand, several CPGs recommended that SUP should be discontinued when there was no risk factor for stress ulcer or the patient could tolerate enteral feeding. Because of the negligence of the duration under the heavy operation work and the misconception of that “the longer duration, the better efficacy”, surgeons always prolonged the duration of prophylaxis. Hence, pharmacist should pay more attentions on the duration and remind the surgeons when the drugs should be discontinued as soon as possible.

Based on our analysis, the clinical pharmacist intervention could save the unnecessary SUP costs and the benefit-to-cost ratio was almost 13:1, showing an economically beneficial effect for both the hospital and patients. In the past, the “drug-maintaining-medicine” has long been a particular character in the health care system in China, which means covering hospital expenses with medicine revenue. However, this old system caused some serious problems including the waste of medical resources, the unreasonably excessive profit of pharmaceutical factory, the serious economic burden of patients and more seriously, the side effects and harm to patients’ health. In order to solve these problems, many policies are implemented in China to change the hospital’s reliance on drugs sales such as the zero bonus of drugs. In this kind of environment, the cost benefit of clinical pharmacists could play a very important role for saving costs of medicines. Moreover, in developing countries like China, the ratio of patients to doctors is very high, which means that the doctors have very heavy work for diagnose and operation. Thus, it’s very difficult for doctors to focus on the rational use of drugs, especially for surgeons. Therefore, pharmacist intervention could help check the rationality of prescription and release these burdens of doctors, guaranteeing the efficacy of drugs, safety of health and economical efficiency of patients.

Even if many advantages of pharmacist intervention in China, clinical pharmacists are only able to make suggestions to the doctors or refuse to dispense prescriptions when inappropriate prescriptions are identified. If the doctors refuse to accept their suggestions, their intervention could not play its role. During the first month of the intervention stage, the rate of surgeons with resistance to the pharmacist’s advices reached approximately 70% because of the surgeons’ misconceptions or prescribing habits. With the efforts of pharmacist’s continual communications, most of the surgeons gradually recognized the disadvantages of inappropriate use of prophylactic acid suppressant and finally accepted the pharmacist’s suggestions, which led to the reduction of resistance rate to approximately 30% during the later stages. Even though, the surgeons were not willing to completely accept the clinical pharmacist’s advice. Thus, it was difficult for the clinical pharmacist to further reduce the irrational use of prophylactic acid suppressant. In order to maximize the effect of clinical pharmacist intervention, hospital administrators should increase the number of clinical pharmacists or prolong the working time of clinical pharmacists to enhance communication between clinical pharmacists and surgeons, and to extend this intervention to other surgical departments. Moreover, clinical pharmacists should be authorized to deny irrational prescriptions.

Unfortunately, our study had several limitations. First, this intervention study was performed on the basis of a pre-to-post design without involving a simultaneous control group, so this retro-prospective study was less convincing than a prospective, controlled study design. Second, this was a single center and a single post-implementation period evaluation of SUP managed by clinical pharmacists. Ideally, another post-implementation period (ie, fourth quarter 2017) may be needed to confirm a sustained impact. Third, although we observed a significant reduction of inappropriate SUP in hospitalized patients in hepatobiliary surgery during intervention phase, the result (10.65%) was not satisfied. We will take further measures
to rectify administration route and shorten SUP duration in the future. Lastly, we utilized identical time periods to eliminate any potential seasonal influence, but we did not identify any other factors that could potentially have influenced the use of acid suppression agents such as shortage of medicine and turnover of surgeons in this teaching hospital during the study periods. These favorable results obtained could not be attributed solely to the clinical pharmacist intervention. Therefore, the reliability of clinical pharmacist intervention needs to be confirmed in more rigorous studies.

Conclusion
The present study demonstrated that implementation of real-time clinical pharmacists intervention for SUP in hepatobiliary surgery improved the appropriate utilization of acid suppressants as well as resulted in favorable economic outcomes. Considering the cost-benefit value, hospital administrators should prolong working time of clinical pharmacists or increase the number of clinical pharmacists to monitor prophylactic acid suppressants. In the future, clinical pharmacists would try their best to expand pharmacists’ practice scope to improve prescription rationality and medication monitoring in general practices.

Acknowledgments
The authors thank the clinical pharmacists who implemented the intervention during the study period.

Author Contributions
Funding acquisition: Hongli Luo.
Investigation: Kun Chen.
Methodology: Hongli Luo.
Project administration: Shunlin Xiao.
Software: Kun Chen.
Supervision: Shunlin Xiao.
Writing – original draft: Hongli Luo.
Writing – review & editing: Qingze Fan.

References
1. Madsen KR, Lorentzen K, Clausen N, Oberg E, Kirkegaard PR, Maymann-Holler N, et al. Guideline for stress ulcer prophylaxis in the intensive care unit. Dan Med J. 2014; 61(3):C4811. PMID: 24814922.
2. Farrell CP, Mercogliano G, Kurtz CL. Overuse of stress ulcer prophylaxis in the critical care setting and beyond. J Crit Care. 2010; 25(2):214–20. https://doi.org/10.1016/j.jcrc.2009.05.014 PMID: 19683892.
3. Hatch JB, Schulz L, Fish JT. Stress ulcer prophylaxis: reducing non-indicated prescribing after hospital discharge. Ann Pharmacother. 2010; 44(10):1565–71. https://doi.org/10.1345/aph.1P167 PMID: 20841521.
4. Amaral MC, Favas C, Alves JD, Riso N, Riscado MV. Stress-related mucosal disease: incidence of bleeding and the role of omeprazole in its prophylaxis. Eur J Intern Med. 2010; 21(6):386–8. https://doi.org/10.1016/j.ejim.2010.06.010 PMID: 20816590.
5. Janicki T, Stewart S. Stress-ulcer prophylaxis for general medical patients: a review of the evidence. J Hosp Med. 2007; 2(2):86–92. https://doi.org/10.1002/jhm.177 PMID: 17427249.
6. Agee C, Coulter L, Hudson J. Effects of pharmacy resident led education on resident physician prescribing habits associated with stress ulcer prophylaxis in non-intensive care unit patients. Am J Health Syst Pharm. 2015; 72(11 Suppl 1):S48–S52. https://doi.org/10.2146/ap150013 PMID: 25991596.
Impact of clinical pharmacist interventions on acid suppressant use in hepatobiliary surgery

7. Ye ZK, Liu Y, Cui XL, Liu LH. Critical Appraisal of the Quality of Clinical Practice Guidelines for Stress Ulcer Prophylaxis. PLoS One. 2016; 11(5):e0155020. https://doi.org/10.1371/journal.pone.0155020 PMID: 27152836

8. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm. 1999; 56 (4):347–79. PMID: 10690219.

9. Gupta R, Garg P, Kutoor R, Munoz JC, Jamal MM, Lambiase LR, et al. Overuse of acid suppression therapy in hospitalized patients. South Med J. 2010; 103(3):207–11. https://doi.org/10.1097/SMJ.0b013e1811ce0e7a PMID: 20134378.

10. Khalili H, Dashi-Khavidaki S, Hossein Talasaz AH, Tabeeefar H, Hendoiee N. Descriptive analysis of a clinical pharmacy intervention to improve the appropriate use of stress ulcer prophylaxis in a hospital infectious disease ward. J Manag Care Pharm. 2010; 16(2):114–21. https://doi.org/10.18553/jmcp.2010.16.2.114 PMID: 20178396.

11. Shin JS, Abah U. Is routine stress ulcer prophylaxis of benefit for patients undergoing cardiac surgery? Interact Cardiovasc Thorac Surg. 2012; 14(5):622–8. https://doi.org/10.1093/icvts/ivs19 PMID: 22345061

12. Bez C, Perrottet N, Zingg T, Leung Ki EL, Demartines N, Pannatier A. Stress ulcer prophylaxis in non-critically ill patients: a prospective evaluation of current practice in a general surgery department. J Eval Clin Pract. 2013; 19(2):374–8. https://doi.org/10.1111/j.1365-2753.2012.01838.x PMID: 22420909.

13. Luo HL, Xiao SL, Wei QM. Investigation and analysis of the use of proton pump inhibitors in inpatients. Chinese Journal of Drug Application and Monitoring. 2015; 12(06):372–5.

14. Rodriguez LA, Ruizgomez A, Wallander MA, Johansson S. Acid-suppressive drugs and community-acquired pneumonia. Epidemiology. 2009; 20(6):800–6. https://doi.org/10.1097/EDE.0b013e3181b527fd PMID: 19797970.

15. Chandra S, Agarwal D, Surana A. Risk of Clostridium difficile infection with acid-suppressive therapy: pitfalls in accurate estimation. Am J Gastroenterol. 2013; 108(2):277–8. https://doi.org/10.1038/aaj.2012.394 PMID: 23381074.

16. Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011; 183(3):310–9. https://doi.org/10.1503/cmaj.092129 PMID: 21173070

17. Abraham NS. Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol. 2012; 28(3):615–20. https://doi.org/10.1097/MOG.0b013e328358db9 PMID: 23010681.

18. Zhao B, Xie XC, Wang ZH, Wei KH. Epidemiological characteristics of adverse reaction of H2 receptor antagonist based on database analysis. Clin Hosp Pharm J. 2014; 34(08):675–8.

19. Zhang HX, Li X, Huo HQ, Liang P, Zhang JP, Ge WH. Pharmacist interventions for prophylactic antibiotic use in urological inpatients undergoing clean or clean-contaminated operations in a Chinese hospital. PLoS One. 2014; 9(2):e88971. https://doi.org/10.1371/journal.pone.0088971 PMID: 24586465

20. Wang J, Dong M, Lu Y, Zhao X, Li X, Wen A. Impact of pharmacist interventions on rational prophylactic antibiotic use and cost saving in elective cesarean section. Int J Clin Pharmacol Ther. 2015; 53(8):605–15. https://doi.org/10.5414/CP202334 PMID: 26104036.

21. Avery AJ, Rodgers S, Cantrill JA, Armstrong S, Cresswell K, Eden M, et al. A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis. Lancet. 2012; 379(9823):1310–9. https://doi.org/10.1016/S0140-6736(11)61817-5 PMID: 22357106

22. Michal J, Henry T, Street C. Impact of a pharmacist-driven protocol to decrease proton pump inhibitor use in non-intensive care hospitalized adults. Am J Health Syst Pharm. 2016; 73(17 Suppl 4):S126–32. https://doi.org/10.2146/ahjp150519 PMID: 27543598.

23. Tasaka CL, Burg C, VanOs dol SJ, Bekeart L, Anglem yer A, Tsouroun is C, et al. An interprofessional approach to reducing the overutilization of stress ulcer prophylaxis in adult medical and surgical intensive care units. Ann Pharmacother. 2014; 48(4):462–9. https://doi.org/10.1177/1060028013517088 PMID: 24473490.

24. Buckley MS, Park AS, Anderson CS, Barletta JF, Bikin DS, Gerkin RD, et al. Impact of a clinical pharmacist stress ulcer prophylaxis management program on inappropriate use in hospitalized patients. Am J Med. 2015; 128(8):905–13. https://doi.org/10.1016/j.amjmed.2015.02.014 PMID: 25820164.

25. Luo HL, Ye Y, Wang SR, Xiao SL, Liu D. The analysis of prophylactic antibiotic use in perioperative period before and after antibiotic special campaign. Chongqing Medicine. 2012; 41(32):3448–50.

26. Frelinger AL 3rd, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy
volunteers. J Am Coll Cardiol. 2012; 59(14):1304–11. https://doi.org/10.1016/j.jacc.2011.12.024 PMID: 22464259.

27. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008; 336(7634):2–3. https://doi.org/10.1136/bmj.39406.449456.BE PMID: 18174564

28. Alqudah MA, Al-Azzam S, Alzoubi K, Alkhatatbeh M, Rawashdeh N. Overuse of proton pump inhibitors for stress ulcer prophylaxis in Jordan. Int J Clin Pharmacol Ther. 2016; 54(8):597–602. https://doi.org/10.5414/CP202533 PMID: 27125772.

29. Zeitoun A, Zeineddine M, Dimassi H. Stress ulcer prophylaxis guidelines: Are they being implemented in Lebanese health care centers? World J Gastrointest Pharmacol Ther. 2011; 2(4):27–35. https://doi.org/10.4292/wjgpt.v2.i4.27 PMID: 21860840

30. Barletta JF, Sclar DA. Use of proton pump inhibitors for the provision of stress ulcer prophylaxis: clinical and economic consequences. Pharmacoeconomics. 2014; 32(1):5–13. https://doi.org/10.1007/s40273-013-0119-5 PMID: 24271943.

31. Ahn JS, Eom CS, Jeon CY, Park SM. Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. World J Gastroenterol. 2013; 19(16):2560–8. https://doi.org/10.3748/wjg.v19.i16.2560 PMID: 23674860

32. Allen ME, Kopp BJ, Erstad BL. Stress ulcer prophylaxis in the postoperative period. Am J Health Syst Pharm. 2004; 61(6):588–96. PMID: 15061430.

33. Grube RR, May DB. Stress ulcer prophylaxis in hospitalized patients not in intensive care units. Am J Health Syst Pharm. 2007; 64(13):1396–400. https://doi.org/10.2146/ajhp060393 PMID: 17592004.

34. Hammond DA, Kathe N, Shah A, Martin BC. Cost-Effectiveness of Histamine2 Receptor Antagonists Versus Proton Pump Inhibitors for Stress Ulcer Prophylaxis in Critically Ill Patients. Pharmacotherapy. 2017; 37(1):43–53. https://doi.org/10.1002/phar.1859 PMID: 27809338.

35. Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthelemy O, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol. 2010; 56(2):134–43. https://doi.org/10.1016/j.jacc.2009.12.071 PMID: 20620727.